Evidence map›Paper›PMID 26854235›Full record

ArticleCell reports2016

KRAS Engages AGO2 to Enhance Cellular Transformation.

Sunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Anastasia K Yocum, Harika Gundlapalli, Yasmine White, Ari Firestone, Xuhong Cao and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Dynamic regulation of RAS and RAS signaling.The Biochemical journal · 2023
    Article
  13. Article
  14. Interplay between K-RAS and miRNAs.Trends in cancer · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Sunita ShankarMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Sethuramasundaram PitchiayaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Single Molecule Analysis Group, Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Rohit MalikMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Vishal KothariMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Yasuyuki HosonoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Anastasia K YocumMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Harika GundlapalliMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Yasmine WhiteDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Ari FirestoneDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Xuhong CaoMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Saravana M DhanasekaranMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Jeanne A StuckeyLife Science Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Gideon BollagPlexxikon Inc., Berkeley, CA 94710, USA.
Kevin ShannonDepartment of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Nils G WalterSingle Molecule Analysis Group, Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.
Chandan Kumar-SinhaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: arul@umich.edu.
University of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · USUniversity of California, San Francisco · USHoward Hughes Medical Institute · USPlexxikon (United States)UCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

UCCRC--ETIOLOGY OF TREATMENT-INDUCED SECONDARY LEUKEMIAP01CA040046 · NCI · UNIVERSITY OF CHICAGO · PI LE BEAU, MICHELLE M · 1985 to 2012
$19.9M
Translational Investigation of KRas & NF1 in Myeloid LeukemiaR37CA072614 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANNON, KEVIN M. · 2007 to 2016
$3.4M
Identification and Characterization of Gene Fusions in Lung AdenocarcinomaR01CA154365 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BEER, DAVID GEORGE, CHINNAIYAN, ARUL M · 2011 to 2015
$1.4M
HCV biology and inhibition visualized at the single molecule levelR21AI109791 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WALTER, NILS G · 2014 to 2015
$428k
Howard Hughes Medical InstituteNCI NIH HHS P01 CA040046NCI NIH HHS R01 CA154365NCI NIH HHS R37 CA072614NCI NIH HHS R37 CA40046NIAID NIH HHS 1R21 AI109791NIAID NIH HHS R21 AI109791
6 · The paper itself

Abstract

Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant KRAS-dependent cells and AGO2 overexpression enhances KRAS(G12V)-mediated transformation. Using AGO2-/- cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsArgonaute ProteinsBase SequenceCarboxypeptidasesCell Transformation, NeoplasticEndoplasmic ReticulumGene SilencingHumansMiceMicroRNAsMolecular Sequence DataMutationNIH 3T3 CellsPhosphatidylinositol 3-KinasesProtein BindingAGO2 protein, humanArgonaute ProteinsCarboxypeptidasesKRAS protein, humanMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)RNA, Small InterferingSCPEP1 protein, humanArgonaute 2cancerEIF2C2KRASRNA silencing

Identifiers

PMID26854235
PMCPMC4758864
OpenAlexW2271216541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.